CCM Duopharma partners India’s Natco and Biocon to offer affordable cancer and insulin therapies

CCM Duopharma Biotech Bhd (CCMD) has partnered with India’s Natco Pharma Limited (Natco) and Biocon Limited (Biocon) to offer affordable cancer and insulin therapies in Malaysia.
CCMD, a subsidiary of Chemical Company of Malaysia Bhd (CCM), signed a 15-year partnership with Natco to build Malaysia’s first High Active Potent Ingredient Drug (HAPI) manufacturing facility to produce generic oncology medicines.
The signing ceremonies, held earlier today, were witnessed by Prime Minister Datuk Seri Najib Tun Razak who was in India for a five-day official visit.
In a statement, CCMD said Natco will provide facility design, manufacturing technology transfer as well as active pharmaceutical ingredients (API) to localize the manufacturing of eight cancer products in Malaysia over the next seven years.
It said the project has been proposed for the Entry Point Project under the National Key Economic Areas by government delivery unit, PEMANDU and will see CCMD allocate a total investment of RM34 million.
Separately, CCMD has also been authorized by Biocon to be the reseller of human insulin in Malaysia following the award of a RM300 million contract under the Ministry of Health’s Off Take programme.
The programme will supply human insulin to all government hospitals and clinics for a period of three years until Dec 1, 2019.
Chairman of CCM, Datuk Normala Abdul Samad, said the strategic alliances with global leaders such as Biocon and Natco solidifies their position as a key player in the Malaysian pharmaceutical industry.
“It is also a stepping stone to help us move up the pharma industry value chain in Asia, and strengthen our capabilities from developing generic pharmaceuticals, leveraging on the expiry of innovator patents to marketing and distribution.
“Through the partnerships, we also hope to offer Malaysians and those in neighbouring countries affordable and high quality treatment options in line with our philosophy ‘Enhancing Quality of Life’,” she added.



Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types